[1]薛清萍,王保庆,朱园园,等.替吉奥与奥沙利铂治疗对复发转移性食管癌患者总生存期与不良反应发生率的影响[J].医学信息,2026,39(02):106-110.[doi:10.3969/j.issn.1006-1959.2026.02.019]
　XUE Qingping,WANG Baoqing,ZHU Yuanyuan,et al.Effect of Tegafur, Gimeracil and Oteracil Potassium and Oxaliplatin on Overall Survival and Incidence of Adverse Reactions in Patients with Recurrent and Metastatic Esophageal Cancer[J].Journal of Medical Information,2026,39(02):106-110.[doi:10.3969/j.issn.1006-1959.2026.02.019]
点击复制

替吉奥与奥沙利铂治疗对复发转移性食管癌患者总生存期与不良反应发生率的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
39卷
期数:
2026年02期
页码:
106-110
栏目:
临床证据信息
出版日期:
2026-01-15

文章信息/Info

Title:
Effect of Tegafur, Gimeracil and Oteracil Potassium and Oxaliplatin on Overall Survival and Incidence of Adverse Reactions in Patients with Recurrent and Metastatic Esophageal Cancer
文章编号:
1006-1959（2026）02-0106-05
作者:
薛清萍; 王保庆; 朱园园; 孙 毓
徐州泉山矿务集团总医院肿瘤内科，江苏 徐州 221006
Author(s):
XUE Qingping;  WANG Baoqing;  ZHU Yuanyuan;  SUN Yu
Department of Oncology, General Hospital of Xuzhou Quanshan Mining Group, Xuzhou 221006, Jiangsu, China
关键词:
替吉奥; 奥沙利铂; 复发转移性食管癌; 总生存期; 不良反应
Keywords:
Tegafur;  gimeracil and oteracil potassium;  Oxaliplatin;  Recurrent and metastatic esophageal cancer;  Overall survival;  Adverse reactions
分类号:
R735.1
DOI:
10.3969/j.issn.1006-1959.2026.02.019
文献标志码:
A
摘要:
目的 分析替吉奥与奥沙利铂治疗对复发转移性食管癌患者总生存期与不良反应发生率的影响。方法 选取2022年8月-2024年8月我院诊治的80例复发转移性食管癌患者为研究对象，采用随机数字表法分为研究组与对照组，各组40例。对照组采用替吉奥治疗，研究组在对照组基础上给予奥沙利铂，对比两组临床疗效、肿瘤标志物水平、总生存期、中位无进展生存期、不良反应发生率、生存质量。结果 研究组治疗客观缓解率为42.50%、疾病控制率为67.50%，均高于对照组的25.00%、47.50%（P＜0.05）；两组治疗后血清癌胚抗原（CEA）、糖类抗原199（CA199）、甲胎蛋白（AFP）均低于治疗前，且与对照组比较，研究组CEA、CA199、AFP更低（P＜0.05）；随访1年，研究组总生存期、中位无进展生存期均长于对照组（P＜0.05）；研究组不良反应发生率与对照组对比，差异无统计学意义（P＞0.05）；两组治疗后社会/家庭状况、功能状况、生理状况、情感状况各维度评分及总评分均高于治疗前，且与对照组比较，研究组以上评分更高（P＜0.05）。结论 替吉奥与奥沙利铂联合治疗可延长复发转移性食管癌患者总生存期，提高客观缓解率、疾病控制率及生存质量，降低血清肿瘤标志物水平，且不会增加不良反应发生率，是一种有效、安全的治疗方案。
Abstract:
Objective To analyze the effect of tegafur, gimeracil and oteracil potassium and oxaliplatin on the overall survival and incidence of adverse reactions in patients with recurrent and metastatic esophageal cancer. Methods A total of 80 patients with recurrent or metastatic esophageal cancer, who were diagnosed and treated at our hospital between August 2022 and August 2024, were enrolled as study subjects. Using a random number table method, they were allocated into a study group and a control group, with 40 patients in each group. The control group received therapy with tegafur, gimeracil and oteracil potassium, while the study group received oxaliplatin in addition to the control group′s regimen. The clinical efficacy, levels of tumor markers, overall survival, median progression-free survival, incidence of adverse reactions, and quality of life were compared between the two groups. Results The objective response rate and disease control rate in the study group were 42.50% and 67.50%, respectively, both higher than those in the control group (25.00% and 47.50%) (P<0.05). After treatment, serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199) and alpha-fetoprotein (AFP) were significantly lower than those before treatment in both groups, while compared with the control group, the study group had lower levels of CEA, CA199, and AFP (P<0.05). After one year of follow-up, both overall survival and median progression-free survival were greater in the study group than those in the control group (P<0.05). No statistically significant difference was observed in the overall incidence of adverse reactions between the study group and the control group (P>0.05). After treatment, the scores of the social/family status, functional status, physiological status, emotional status, as well as the total score of the quality-of-life assessment, were significantly improved compared with before treatment scores in both groups, furthermore, the study group exhibited higher scores in each dimension and the total score compared with the control group (P<0.05). Conclusion The combination of tegafur, gimeracil and oteracil potassium and oxaliplatin can prolong the overall survival of patients with recurrent and metastatic esophageal cancer, improve the objective remission rate, disease control rate and quality of life, reduce the level of serum tumor markers, and will not increase the incidence of adverse reactions. It is an effective and safe treatment.

参考文献/References:

[1]张兰芳,陈旭,蒯君,等．替吉奥联合奥沙利铂对老年胃癌患者胃动力相关激素及基质金属蛋白酶 -2、基质金属蛋白酶-9的影响[J].实用临床医药杂志,2024,28(12):57-60,65.[2]贝云枫,何振华,张炼.加味小陷胸汤联合替吉奥与奥沙利铂化疗方案治疗胃癌的疗效分析及对血清胃蛋白酶原、外周血循环肿瘤细胞的影响[J].中华中医药学刊,2023,41(6):255-258.[3]马金鑫,冯谢敏,宋炜,等.氟尿嘧啶联合奥沙利铂或顺铂对晚期食管癌患者的临床疗效[J].中国医药,2022,17(4):549-553.[4]Goto H,Sugita K,Yanagihara S,et al.Shiitake Dermatitis-like Eruption Due to Tegafur/Gimeracil/Oteracil Combination Usage[J].Yonago Acta Med,2017,60(3):179-181.[5]朱梅,程旭,钱晓涛.放疗联合卡瑞利珠单抗或替吉奥治疗局部晚期食管癌的疗效[J].中国肿瘤外科杂志,2023,15(6):536-540.[6]兰峰,孙静,张永辉,等.奥沙利铂联合替吉奥治疗对进展期食管癌患者生存时间的影响[J].贵州医科大学学报,2023,48(10):1204-1208.[7]中华人民共和国国家卫生健康委员会医政医管局.食管癌诊疗指南(2022年版)[J].中华消化外科杂志,2022,21(10):1247-1268.[8]Yang H,Wang F,Hallemeier CL,et al.Oesophageal cancer[J].Lancet,2024,404(10466):1991-2005.[9]魏长江,茅怡铭,秦元,等.顺铂、奥沙利铂或奈达铂在Ⅲ期食管癌新辅助化疗疗效中的对比研究[J].现代肿瘤医学,2021,29(1):57-60.[10]刘丽英,王小倩,倪福春.替吉奥联合奥沙利铂同步放疗治疗老年局部晚期食管癌[J].肿瘤基础与临床,2015，28(4):300-302.[11]Zhao J,Lei J,Yu J,et al.Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma[J].Invest New Drugs,2020,38(2):500-506.[12]苏楠,范霞霞,谢娇娇,等.杨梅素通过抑制能量代谢促进5-氟尿嘧啶对人食管癌细胞EC109的抗肿瘤作用[J].中国药理学与毒理学杂志,2022,36(6):451-458.[13]王清清,朱小红,刘鹏.系统免疫炎症指数预测老年食管癌根治性放疗患者预后的效果分析[J].中外医药研究,2022,1(5):132-134.[14]温永胜.奥沙利铂联合亚叶酸钙及氟尿嘧啶化疗治疗晚期食管癌临床观察[J].临床医药实践,2020,29(3):201-203.[15]李琳,蔡晓军.阿帕替尼联合紫杉醇二线治疗晚期食管癌的临床研究[J].实用肿瘤杂志,2020,35(3):241-244.[16]Cheng XW,Leng WH,Mu CL.Efficacy and safety of S-1 maintenance therapy in advanced non-small-cell lung cancer patients[J].World J Clin Cases,2020,8(21):5172-5179.[17]姜妮,乔国梁,王小利,等.食管癌患者化疗联合细胞免疫治疗前后外周血淋巴细胞亚群变化的分析[J].现代肿瘤医学,2020,28(6):933-938.[18]吴艳,陆颖芝,陶敏.低剂量阿帕替尼联合替吉奥治疗铂类方案 失败复发或转移性头颈部鳞状细胞癌的临床观察[J].肿瘤研究与临床,2020,32(3):197-199.[19]赵秀芹,陈淑娟,陈慧玲.艾迪注射液联合替吉奥及奥沙利铂化疗治疗晚期食管癌的效果和安全性[J].中国实用医刊,2022,49(12):112-115.[20]Pal AK,Raja S.Characterization of Forced Degradants of Tegafur, Gimeracil, and Oteracil Potassium by Liquid Chromatographic-Electrospray Ionization-Mass Spectrometry and Simultaneous Estimation of Triple Combination in Drug Substance and Finished Pharmaceutical Dosage Form[J].Arch Razi Inst,2024,79(2):287-302.[21]Hu L,Kong Z,Meng Q,et al.The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma[J].Med Sci Monit,2020,26:e927221.[22]滕熠,曹毛毛,严鑫鑫,等.1990-2019年早发食管癌疾病负担及变化趋势:中国与全球对比分析[J].中华肿瘤防治杂志,2024,31(4):189-195.[23]渠红,刘敏,谢枫.紫杉醇或5-氟尿嘧啶联合顺铂同步放疗方案治疗老年中晚期食管癌患者的临床效果及安全性[J].中华老年多器官疾病杂志,2021,20(6):439-443.[24]朱建军,吴剑,徐磊荣.阿帕替尼联合替吉奥治疗复发转移食管癌的疗效及对患者QLQ-30评分的影响[J].临床与病理杂志,2021,41(12):2830-2835.[25]孙魏,邹玺,张微,等.安罗替尼联合替吉奥二线治疗复发转移性食管鳞癌的临床疗效[J].南方医科大学学报,2021,41(2):250-255.

更新日期/Last Update: 1900-01-01